OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Dec FDA Decision: Opus Genetics, Inc. (IRD)

The Phase 3 date for OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Dec by Opus Genetics, Inc. (IRD) is scheduled for March 1, 2026. This is the target date for the FDA to make a decision on this application.

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Dec is being developed by Opus Genetics, Inc. for the treatment of its target indication. It is currently in Phase 3 clinical trials.

If OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Dec receives FDA approval, Opus Genetics, Inc. (IRD) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for IRD on DilutionWatch at dilutionwatch.com/stock/IRD.html.

You can view the full BiotechSigns company profile for Opus Genetics, Inc. (IRD) at biotechsign.com/app/company/IRD, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.